tremelimumab   Click here for help

GtoPdb Ligand ID: 8462

Synonyms: CP-675 | CP-675,206 | CP-675206 | ticilimumab
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 [2].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Whilst Phase 2 clinical trials in patients with malignant mesothelioma [1] and uveal melanoma [3] are underway, the US FDA granted tremelimumab orphan drug status for the treatment of malignant mesothelioma (in April 2015), a disease most commonly caused by exposure to asbestos.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tremelimumab stimulates the immune system to destroy cancer cells [4]. Downregulation of T-cell activation is achieved by the antibody blocking the interaction between CTLA4 on T cells and the B7 proteins (CD80 and CD86) on antigen presenting cells. This leaves the unbound B7 proteins free to bind CD28, another T cell surface receptor. The result is a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.